



#2

Patent
Attorney's Docket No. 032775-083

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Matthew C. Coffey

Application No.: 09/985,756

Filed: November 6, 2001

For: METHODS FOR THE TREATMENT OF
CELLULAR PROLIFERATIVE
DISORDERS

)
)
) Group Art Unit: 1635

)
) Examiner: Unassigned
)
)

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

By: _____

Ping F. Hwang
Registration No. 44,164

Date: January 29, 2002



Patent
Attorney's Docket No. 032775-083

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

In re Patent Application of)
Matthew C. Coffey)
Application No.: 09/985,756) Group Art Unit: 1635
Filed: November 6, 2001) Examiner: Unassigned
For: METHODS FOR THE TREATMENT)
OF CELLULAR PROLIFERATIVE)
DISORDERS)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56,
Applicants hereby submit the following information in conformance with 37 C.F.R.
§§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is
enclosed.

United States Patents

	<u>Inventor</u>	<u>Issue date</u>	<u>Patent No.</u>
1.	Hseih	June 11, 1991	5,023,252

Foreign Patents

2.	WO 99/08692	published February 25, 1999.
----	-------------	------------------------------

Articles

3. Archer *et al.* (1995), *Br. J. Cancer* 72:1259-1266.
4. Armstrong, G.D. *et al.* (1984), *Virology* 138:37-48.
5. Barbacid, M., *Annu. Rev. Biochem.*, 56:779-827 (1987).
6. Baselga *et al.* (1996), *J. Clin. Onc.* 14:737-744.
7. Bos, J. (1989) *Cancer Res.* 49:4682-4689.
8. Carter *et al.* (1992), *PNAS* 89:4285-4289.
9. Chandron and Nibert, "Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subviral particle", *J. of Virology* 72(1):467-75 (1998).
10. Chaubert, P. *et al.* (1994), *Am. J. Path.* 144:767-775.
11. Clark *et al.* (1995), *Science* 268:233-239.
12. Clark *et al.* (1996), *Intl. J. Cancer* 65:186-191.
13. Cuff *et al.*, "Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract", *Toxicological Sciences* 42(2):99-108 (1998).
14. DiDomenico *et al.* (1996), *Cancer Res.* 56:4516-4521.
15. Duncan *et al.*, "Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein", *Virology* 182(2):810-819 (1991).
16. Dvorak *et al.* (1988), *Am J Path* 133:95-109.
17. Gentsch, J.R.K. and Pacitti, A.F. (1985), *J. Virol.* 56:356-364.
18. Harwerth *et al.* (1992), *J Biol Chem* 267:15160-15167.
19. Hudziak *et al.* (1989), *Mol Cell Biol* 9:1165-1172.
20. Hung *et al.* (1995), *Gene* 159:65-71.

RECEIVED
FEB 04 2002
TECH CENTER 1600/2900

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

21. Jacobs *et al.* (1983), *Cancer Res* 43:1696-1702.
22. Janes, P.W., *et al.* (1994) *Oncogene* 9:3601-3608.
23. Jardines *et al.* (1993) *Pathobiology* 61:268-282.
24. Koenders *et al.* (1991), *Cancer Res* 51:4544-4548.
25. Lee, J.M. *et al.* (1993) *PNAS* 90:5742-5746.
26. Lee, P.W.K. *et al.* (1981) *Virology*, 108:134-146.
27. Levitzki, A. (1994) *Eur. J. Biochem.* 226:1-13.
28. Lowe, S.W. *et al.* (1994) *Science*, 266:807-810.
29. Mah *et al.*, "The N-terminal quarter of reovirus cell attachment protein sigma 1 possesses intrinsic virion-anchoring function", *Virology* 179(1):95-103 (1990).
30. Migliaccio *et al.* (1996), *EMBO J* 15:1292-1300.
31. Migliaccio *et al.* (1998), *EMBO J* 17:2008-2018.
32. Millis, NE *et al.* (1995) *Cancer Res.* 55:1444.
33. Nagy *et al.* (1989) *Biochim Biophys Acta* 948:305-326.
34. Paul R.W. *et al.* (1989) *Virology* 172:382-385.
35. Pietras *et al.* (1994), *Oncogene* 9:1829-1838.
36. Raybaud-Diogene, H. *et al.* (1997) *J. Clin. Oncology*, 15(3):1030-1038.
37. Rosen, L. (1960) *Am. J. Hyg.* 71:242-249.
38. Shackney *et al.* (1998), *Clin Cancer Res* 4:913-928.
39. Slamon *et al.* (1989), *Science* 244:707-712.
40. Smith, R.E. *et al.*, (1969) *Virology*, 39:791-800.
41. Spandidos (1987), *Anticancer Res* 7:991-996.

42. Stanley, N.F. (1967) *Br. Med. Bull.* 23:150-154.
43. Strong, J.E. *et al.*, (1993) *Virology*, 197:405-411.
44. Strong, J.E. and Lee, P.W.K., (1996) *J. Virol.*, 70:612-616.
45. Strong, J.E. *et al.*, (1998) *EMBO J*, 17:3351-3362.
46. Turner and Duncan, "Site directed mutagenesis of the C-terminal portion of reovirus protein sigma1: evidence for a conformation-dependent receptor binding domain" *Virology* 186(1):219-227 (1992).
47. Verbeek *et al.* (1996) *J Path* 180:383-388.
48. Wiessmuller, L. and Wittinghofer, F. (1994), *Cellular Signaling* 6(3):247-267.
49. Zhou *et al.* (1989), *Oncogene* 4:105-108.

These documents are being submitted within three months of the filing date of the present application. Consequently, no fee is required pursuant to 37 C.F.R. §1.97(b).


By citing the above references, Applicants do not acquiesce or admit that any of these documents are "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____


Ping F. Hwang
Registration No. 44,164
Attorney for Applicants
Redwood Shores, CA Office
(650)-622-2300

P.O. Box 1404
Alexandria, Virginia 22313-1404
Tel: (650) 622-2300

Date: January 29, 2002

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO.
032775-083APPLICATION NO.
09/985,756INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Matthew C. Coffey
FILING DATE
November 6, 2001GROUP
1635

RECEIVED

FEB 04 2002

JAN 30 2002

PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
	5,023,252		Hsieh	6/11/91

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	WO 99/08692		PCT	2/25/99		


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Archer <i>et al.</i> (1995), <i>Br. J. Cancer</i> 72:1259-1266.
	Armstrong, G.D. <i>et al.</i> (1984), <i>Virology</i> 138:37-48.
	Barbacid, M., <i>Annu. Rev. Biochem.</i> , 56:779-827 (1987).
	Baselga <i>et al.</i> (1996), <i>J. Clin. Onc.</i> 14:737-744.
	Bos, J. (1989) <i>Cancer Res.</i> 49:4682-4689.
	Carter <i>et al.</i> (1992), <i>PNAS</i> 89:4285-4289.
	Chandron and Nibert, "Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subviral particle", <i>J. of Virology</i> 72(1):467-475 (1998).
	Chaubert, P. <i>et al.</i> (1994), <i>Am. J. Path.</i> 144:767-775.
	Clark <i>et al.</i> (1995), <i>Science</i> 268:233-239.
	Clark <i>et al.</i> (1996), <i>Intl. J. Cancer</i> 65:186-191.
	Cuff <i>et al.</i> , "Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract", <i>Toxicological Sciences</i> 42(2):99-108 (1998).
	DiDomenico <i>et al.</i> (1996), <i>Cancer Res.</i> 56:4516-4521.
	Duncan <i>et al.</i> , "Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein", <i>Virology</i> 182(2):810-819 (1991).
	Dvorak <i>et al.</i> (1988), <i>Am J Path</i> 133:95-109.
	Gentsch, J.R.K. and Pacitti, A.F. (1985), <i>J. Virol.</i> 56:356-364.
	Harwerth <i>et al.</i> (1992), <i>J Biol Chem</i> 267:15160-15167.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.
032775-083APPLICATION NO.
09/985,756APPLICANT
Matthew C. CoffeyFILING DATE
November 6, 2001GROUP
1635Hudziak *et al.* (1989), *Mol Cell Biol* 9:1165-1172.Hung *et al.* (1995), *Gene* 159:65-71.Jacobs *et al.* (1983), *Cancer Res* 43:1696-1702.Janes, P.W., *et al.* (1994) *Oncogene* 9:3601-3608.Jardines *et al.* (1993) *Pathobiology* 61:268-282.Koenders *et al.* (1991), *Cancer Res* 51:4544-4548.Lee, J.M. *et al.* (1993) *PNAS* 90:5742-5746.Lee, P.W.K. *et al.* (1981) *Virology*, 108:134-146.Levitzki, A. (1994) *Eur. J. Biochem.* 226:1-13.Lowe, S.W. *et al.* (1994) *Science*, 266:807-810.Mah *et al.*, "The N-terminal quarter of reovirus cell attachment protein sigma 1 possesses intrinsic virion-anchoring function" *Virology* 179(1):95-103 (1990).Migliaccio *et al.* (1996), *EMBO J* 15:1292-1300.Migliaccio *et al.* (1998), *EMBO J* 17:2008-2018.Millis, NE *et al.* (1995) *Cancer Res.* 55:1444-1447.Nagy *et al.* (1989) *Biochim Biophys Acta* 948:305-326.Paul R.W. *et al.* (1989) *Virology* 172:382-385.Pietras *et al.* (1994), *Oncogene* 9:1829-1838.Raybaud-Diogene, H. *et al.* (1997) *J. Clin. Oncology*, 15(3):1030-1038.Rosen, L. (1960) *Am. J. Hyg.* 71:242-249.Shackney *et al.* (1998), *Clin Cancer Res* 4:913-928.Slamon *et al.* (1989), *Science* 244:707-712.Smith, R.E. *et al.*, (1969) *Virology*, 39:791-800.Spandidos (1987), *Anticancer Res* 7:991-996.Stanley, N.F. (1967) *Br. Med. Bull.* 23:150-154.Strong, J.E. *et al.*, (1993) *Virology*, 197:405-411.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 ATTORNEY'S DKT NO.
032775-083

 APPLICATION NO.
09/9851756

 APPLICANT
Matthew C. Coffey

 FILING DATE
November 6, 2001

 GROUP
1635

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

Strong, J.E. and Lee, P.W.K., (1996) *J. Virol.*, 70:612-616.Strong, J.E. *et al.*, (1998) *EMBO J*, 17:3351-3362.
 Turner and Duncan, "Site directed mutagenesis of the C-terminal portion of reovirus protein signal: evidence for a conformation-dependent receptor binding domain" *Virology* 186(1):219-227 (1992).
Verbeek *et al.* (1996) *J Path* 180:383-388.Wiessmuller, L. and Wittinghofer, F. (1994), *Cellular Signaling* 6(3):247-267.Zhou *et al.* (1989), *Oncogene* 4:105-108.
 Examiner
Signature

 Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.